Abstract
From November 1976 to June 1982, a randomised clinical trial was carried out at the Christie Hospital, Manchester, to test the clinical efficacy of tamoxifen (TAM) as an adjuvant to surgery for patients with operable breast carcinoma. Following surgery, premenopausal women were randomly allocated to have either TAM 20 mg day-1 for one year or an irradiation menopause (the previous standard treatment). Postmenopausal women had TAM 20 mg day-1 for one year or no further treatment (Controls). A total of 1005 patients were entered into the trial of whom 961 are evaluable at 10 years from the inception. At 10 years the analysis shows no significant difference in overall and disease free survival between premenopausal women given TAM or an irradiation menopause. For premenopausal node negative patients there would appear to be a trend in favour of the TAM treated patients with a 93% ten year survival vs. 82% for the irradiation menopause group (P = 0.09). When the disease free survival of all 961 patients is analysed, allowing for node status, then there is a marked trend in favour of the TAM treated patients (P = 0.07). Of the patients originally allocated to TAM 47% had an irradiation menopause on relapse and 73% of the postmenopausal control patients had TAM on relapse. The incidence of side effects and second primary tumours is discussed as well as the possible effects of varying the length of time over which adjuvant TAM is administered.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ribeiro, G., Swindell, R. The Christie hospital adjuvant tamoxifen trial – status at 10 years. Br J Cancer 57, 601–603 (1988). https://doi.org/10.1038/bjc.1988.136
Issue Date:
DOI: https://doi.org/10.1038/bjc.1988.136
This article is cited by
-
Tamoxifen evolution
British Journal of Cancer (2023)
-
Effects of tamoxifen on vaginal blood flow and epithelial morphology in the rat
BMC Women's Health (2006)
-
Endocrinology and hormone therapy in breast cancer: Endocrine therapy in premenopausal women
Breast Cancer Research (2005)
-
What caused the decline in breast cancer mortality in the united kingdom?
Breast Cancer (2004)
-
Laboratory models of breast and endometrial cancer to develop strategies for antiestrogen therapy
Breast Cancer (1998)